The Practices with Data Integrity Risk (DI Risk)

What are the practices with data integrity risk?

Data integrity (DI) issues and data integrity risks related to those issues are very serious problems for any organization.

There are many practices that are being followed in the pharmaceutical industry also. Here are presented some practices with data integrity risk.

Data Integrity Issue 1 :

Data recording in personnel notes, loose sheets of paper or sticky notes, followed by transcription in original documents.

DI Risk related to Issue:

  1. Allows manipulation of data as GxP records can be written after events.
  2. No evidence of original data recording in a GxP document, and no traceability.
  3. Chances of potential transcription error.

Data Integrity Issue 2 :

Raw data is discarded after transcription in records, or no data to support the records.

DI Risk related to Issue:

No evidence of the authenticity of the recorded value.

Data Integrity Issue 3 :

Backdating of records, signing records at a later time with past date and time.

DI Risk related to Issue:

  1. Questions of authenticity of all records & data.
  2. Indicates a lack of oversight and control.

Data Integrity Issue 4 :

Reporting results without performing the task. or Employees who signed were not available on premises at the time of activity completed.

DI Risk related to Issue:

  1. Intentional fraud and fabrication of data.
  2. Questions of all the results by individuals, groups or organizations.

Data Integrity Issue 5 :

Activity not recorded contemporaneously.

DI Risk related to Issue:

  1. Potential data loss/error
  2. Difficult to rely on data generated

Data Integrity Issue 6 :

Destruction of records and data without justification and without proper recording of destruction activity.

DI Risk related to Issue:

  1. Indicating selecting recording only (Good data only recorded)
  2. The data set is no longer complete
  3. Provides opportunities to ignore failing results

Data Integrity Issue 7 :

Re-running the sample to obtain better results. (Trial injection, repeat analysis without suitable justification, not all results reported)

DI Risk related to Issue:

  1. Testing into compliance
  2. Borderline results passed due to method variability, selective data reported
  3. Potentially failing samples in “trial injection” was replaced by passing batch, indicating a lack of confidence in the method and product quality.

Data Integrity Issue 8 :

Data falsification (change in integration parameters of chromatographic data to obtain passing results.

DI Risk related to Issue:

  1. Indicated falsification of data
  2. intentional fraud

Data Integrity Issue 9 :

Common user access login for computerized systems

DI Risk related to Issue:

  1. No traceability of operation execution and data deletion
  2. Access control and user rights can not be implemented
  3. No control over who can do what

Data Integrity Issue 10 :

Sharing password

DI Risk related to Issue:

  1. No traceability of operation execution of the actual user
  2. Bypasses the access control and user right system
  3. Potential for deletion of the non-satisfactory data.

Data Integrity Issue 11 :

Audit trail disable or not fully enabled.

Data Integrity Risks related to the Issue:

  1. Doesn’t provide a complete record of activity
  2. Allows data manipulation and data deletion without any justification, selective data can be deleted
  3. Allows potential backdating by changing system date and time

These are some DI issues and data integrity risks associated with that issues.

data integrity risk
Data Integrity Risk

Also read:

Refer YT Channel: Pharmabeejpro

Leave a Comment

20 + 4 =